Spain's Farmaindustria demands a Sectorial Plan 'because laboratories have nothing else left to give'
During its recent general assembly, Spanish drugs trade group Farmaindustria's president and director general, Jesus Acebillo and Humberto Arnes, respectively, analysed the impacts that the Royal Decree-Laws 4/2010 of March 26 and 8/2010 of May 20 will have on the pharmaceutical industry.
The decrees were described as a 'mortal blow' to Spain's pharmaceutical sector, cutting the prices of patented prescription drugs by as much as 23% in the hope of reducing what the public health system spends on medicines. The savings should amount to roughly 1.3 billion euros ($1.64 billion; The Pharma Letter May 17).
Will result in reduced investment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze